RELMADA THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $26.9M | $46.2M | $54.8M | $113.3M | $90.6M |
| Operating expenses | $59.1M | $83.9M | $103.7M | $161.2M | $125.7M |
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M | -$125.8M |
| Balance Sheet | |||||
| Cash and equivalents | $3.5M | $3.9M | $4.1M | $5.4M | $44.4M |
| Current assets | $94.0M | $45.8M | $97.5M | $152.9M | $223.3M |
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M |
| Current liabilities | $6.4M | $10.3M | $12.2M | $12.5M | $15.1M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M |
| Stockholders' equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M |
| Depreciation and amortization | — | — | — | — | $1,258 |
| Stock-based compensation | $13.9M | $30.2M | $43.8M | $44.2M | $40.5M |
Shares outstanding 104.9M · Free float 94.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.